Disparities exist in survival among younger patients with acute leukemia
the ONA take:
Disparities in treatment outcomes for younger patients with acute promyelocytic leukemia (APL) exist among uninsured patients and those of Hispanic and black race/ethnicity, according to a new study published online ahead of print in the journal Cancer.
For the study, researchers sought to evaluate disparities in early death and survival in children, adolescents, and young adults with APL in California in the era of all-trans-retinoic acid (ATRA) treatment.
Researchers analyzed data from the California Cancer Registry to assess the 7-day and 30-day mortality and survival in 772 patients younger than 39 years of age with APL who were diagnosed between 1988 and 2011.
Results showed that the overall 30-day mortality decreased from 26% between 1988 and 1995 to 14% between 2004 and 2011, suggesting that the odds of death in the 30 days after diagnosis were 3 times higher during the first time period than the second time period.
Researchers found that lack of insurance and Hispanic and black race/ethnicity were associated with higher early death and reduced survival, suggesting that efforts should be made to improve access to effective treatment among those patients.
Disparities in treatment outcomes for younger patients with acute promyelocytic leukemia (APL) exist.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|